Novo Nordisk May Withhold Xultophy From Germany If Price Talks Fail
This article was originally published in The Pink Sheet Daily
Executive Summary
Denmark's diabetes specialist says it may decide not to sell Xultophy in Germany if a high-enough price cannot be negotiated there for the new fixed dose combination of insulin degludec and liraglutide for type 2 diabetes.